Company intelligence / Profile preview

AFYREN

Ownership: Private
Development stage: Commercial

Overview

AFYREN has achieved continuous industrial-scale production at its first plant (AFYREN NEOXY), producing seven types of bio-based organic acids from agricultural by-products. The company has secured €165 million in revenue through multi-year contracts and aims to ramp up annual production revenue to around €35 million at full capacity. Products are being qualified for delivery under these contracts.

Industry: Non-Drug Biotech

Drug pipeline

7 assets

biobased acetic acid

Commercial

6 more assets in the full pipeline.

Request access →

Partnerships

SüdzuckerCearitisBpifrance’s SPI Fund

Beyond the preview

Go deeper on AFYREN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFYREN.

Explore the full profile